| Treatment of renal cell carcinoma: current status and future directions PC Barata, BI Rini CA: a cancer journal for clinicians 67 (6), 507-524, 2017 | 715 | 2017 |
| Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma VS Koshkin, PC Barata, T Zhang, DJ George, MB Atkins, WJ Kelly, ... Journal for immunotherapy of cancer 6, 1-7, 2018 | 174 | 2018 |
| RNA-targeted therapeutics in cancer clinical trials: Current status and future directions P Barata, AK Sood, DS Hong Cancer treatment reviews 50, 35-47, 2016 | 158 | 2016 |
| Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA N Agarwal, SK Pal, AW Hahn, RH Nussenzveig, GR Pond, SV Gupta, ... Cancer 124 (10), 2115-2124, 2018 | 95 | 2018 |
| PSMA theranostics: Review of the current status of PSMA-targeted imaging and radioligand therapy W Jones, K Griffiths, PC Barata, CJ Paller Cancers 12 (6), 1367, 2020 | 93 | 2020 |
| Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA P Barata, N Agarwal, R Nussenzveig, B Gerendash, E Jaeger, W Hatton, ... Journal for immunotherapy of cancer 8 (2), 2020 | 86 | 2020 |
| Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance PC Barata, VS Koshkin, P Funchain, D Sohal, A Pritchard, S Klek, ... Annals of Oncology 28 (10), 2458-2463, 2017 | 77 | 2017 |
| Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors AR Khaki, A Li, LN Diamantopoulos, MA Bilen, V Santos, J Esther, ... Cancer 126 (6), 1208-1216, 2020 | 76 | 2020 |
| Metastatic castration‐sensitive prostate cancer: abiraterone, docetaxel, or… PC Barata, AO Sartor Cancer 125 (11), 1777-1788, 2019 | 72 | 2019 |
| Outcomes and satisfaction of two optional cadaveric dissection courses: A 3‐year prospective study D Pais, D Casal, L Mascarenhas‐Lemos, P Barata, BJ Moxham, ... Anatomical Sciences Education 10 (2), 127-136, 2017 | 65 | 2017 |
| Seamless designs: current practice and considerations for early-phase drug development in oncology BP Hobbs, PC Barata, Y Kanjanapan, CJ Paller, J Perlmutter, GR Pond, ... JNCI: Journal of the National Cancer Institute 111 (2), 118-128, 2019 | 61 | 2019 |
| Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab H Zahoor, PC Barata, X Jia, A Martin, KD Allman, LS Wood, TD Gilligan, ... Journal for Immunotherapy of Cancer 6, 1-8, 2018 | 61 | 2018 |
| A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors AR Khaki, A Li, LN Diamantopoulos, NJ Miller, L Carril-Ajuria, ... European urology oncology 4 (3), 464-472, 2021 | 46 | 2021 |
| The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma PC Barata, AG De Liano, P Mendiratta, V Crolley, B Szabados, L Morrison, ... British journal of cancer 119 (2), 160-163, 2018 | 46 | 2018 |
| Randomized phase II trial of sipuleucel-T with or without radium-223 in men with bone-metastatic castration-resistant prostate cancer CH Marshall, W Fu, H Wang, JC Park, TL DeWeese, PT Tran, DY Song, ... Clinical Cancer Research 27 (6), 1623-1630, 2021 | 44 | 2021 |
| Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer F Taza, AE Holler, W Fu, H Wang, N Adra, C Albany, R Ashkar, HH Cheng, ... JCO Precision Oncology 5, 1200-1220, 2021 | 41 | 2021 |
| Circulating tumor DNA alterations in advanced urothelial carcinoma and association with clinical outcomes: a pilot study P Grivas, AKA Lalani, GR Pond, RJ Nagy, B Faltas, N Agarwal, SV Gupta, ... European urology oncology 3 (5), 695-699, 2020 | 39 | 2020 |
| Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study VS Koshkin, N Henderson, M James, D Natesan, D Freeman, A Nizam, ... Cancer 128 (6), 1194-1205, 2022 | 36 | 2022 |
| Histological subtypes and response to PD-1/PD-L1 blockade in advanced urothelial cancer: a retrospective study NJ Miller, AR Khaki, LN Diamantopoulos, MA Bilen, V Santos, N Agarwal, ... The Journal of urology 204 (1), 63-70, 2020 | 36 | 2020 |
| Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer EM Ledet, MB Lilly, G Sonpavde, E Lin, RH Nussenzveig, PC Barata, ... The oncologist 25 (4), 327-333, 2020 | 34 | 2020 |
